Genital Herpes Vaccine to Move Toward Clinical Testing

Feb. 28, 2013 - PRLog -- The Center for the Biology of Chronic Disease (CBCD) recently learned that according to an article on seekingalpha.com, “under a grant from the National Institute of Allergy and Infectious Diseases Division of the National Institutes of Health (NIH), [Vical Incorporated (VICL)] has mounted an effort directed at developing a plasmid DNA-based vaccine to inhibit recurring lesions in patients latently infected with HSV-2.”

These efforts are still in the pre-clinical phase. However, interestingly, “results have shown a reproducible statistically significant reduction in viral lesion occurrence in guinea pigs latently infected with HSV-2.”

What does this mean?

In layman terms, there were not as many herpes virus lesions in the guinea pigs being tested.

Because of the statistically significant findings revealed by Vical, the company has decided to move forward with clinical testing that is expected to begin in the latter half of 2013. The CBCD believes this is an incredibly interesting development and potentially highly profitable one since “Current estimates suggest that a therapeutic HSV-2 vaccine could generate as much as a billion dollars in annual sales at its peak.”

Genital herpes is one of the more common sexually transmitted diseases in the United States. The CBCD is in favor of all methods of prevention. Helping women to increase their awareness about possible exposure risks is very important.

After an initial period of activity where there can be up to 5 major outbreaks in a year, Herpes establishes what scientists call a latent infection. When a virus is latent, it acts as if it is asleep. It is dormant. The moment your immune system is weakened however, the Herpes virus can “wake up” and become active again.

Until a safe and effective genital herpes vaccine enters the market, the CBCD stresses that the best defense against a latent herpes infection is a healthy immune system.

That’s why the CBCD would like to point out a Herpes remedy that boosts the immune system and helps target the dormant (latent) HSV virus.

“The key to your health is to reduce the level of the chronic viruses in your body to harmless levels.” – Dr. Hanan Polansky

The name of that antiviral remedy is Gene-Eden-VIR. This all-natural product was scientifically designed to help the human body maintain low concentrations of the dormant or latent herpes virus.

By helping the body’s immune system target the latent herpes virus, people also lower their risk of developing fever blisters, cold sores, or genital herpes symptoms. This is just one reason the CBCD believes Gene-Eden-VIR is an important product.

Visit http://www.gene-eden-kill-virus.com today to learn more about Gene-Eden-VIR, the only product on the market today that helps the body target the latent herpes virus and that is scientifically backed by published material.

###

The Center for the Biology of Chronic Disease (CBCD, http://www.cbcd.net) is a research center recognized by the IRS as a 501(c)(3) non-for-profit organization. The mission of the CBCD is to advance the research on the biology of chronic diseases, and to accelerate the discovery of treatments for these diseases.

The CBCD published the “Purple” book entitled “Microcompetition with Foreign DNA and the Origin of Chronic Disease” written by Dr. Hanan Polansky. The book presents Dr. Polansky’s highly acclaimed scientific theory on the relationship between the DNA of latent (chronic) viruses and the onset of chronic diseases. Dr. Polansky’s book is available as a free download from the CBCD website.

We invite biologists, virologists, and scientists everywhere to download Dr. Polansky’s book here:http://cbcd.net/.